The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome.
- DOI
- 10.1155/2022/4807175
- Published
- 2022
- Container
- Evidence-based complementary and alternative medicine : eCAM
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
serious concern Score 10/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- serious concernRetraction Watch retraction: 1 retraction notice matched this DOI.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1155/2022/4807175,
title = {The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome.},
author = {Liu Z and Qiu X and Yang H and Wu X and Ye W and Zheng X},
year = {2022},
journal = {Evidence-based complementary and alternative medicine : eCAM},
doi = {10.1155/2022/4807175},
url = {https://doi.org/10.1155/2022/4807175}
}RIS
TY - JOUR TI - The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome. AU - Liu Z AU - Qiu X AU - Yang H AU - Wu X AU - Ye W AU - Zheng X PY - 2022 JO - Evidence-based complementary and alternative medicine : eCAM DO - 10.1155/2022/4807175 UR - https://doi.org/10.1155/2022/4807175 ER -
APA
Z, L., X, Q., H, Y., X, W., W, Y., & X, Z. (2022). The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome.. Evidence-based complementary and alternative medicine : eCAM. https://doi.org/10.1155/2022/4807175
Source records
- pubmed · retrieved 2026-09-24T22:33:43.936Z